Matches in SemOpenAlex for { <https://semopenalex.org/work/W2539214151> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2539214151 endingPage "S17" @default.
- W2539214151 startingPage "S17" @default.
- W2539214151 abstract "Recurrent GBM and AA have a dismal prognosis and a high unmet need for effective therapies. Toca 511 (vocimagene amiretrorepvec) is an investigational retroviral replicating vector that encodes the transgene cytosine deaminase (CD). Toca 511 selectively infects, persists and spreads in tumor. Subsequent oral administration of 5-fluorocytosine (Toca FC) produces 5-fluorouracil (5-FU) by CD within infected cells. 5-FU kills cancer cells and myeloid derived suppressor cells, inducing robust antitumor immune responses in animal models. Clinical data from phase 1 trials are consistent with this mechanism of action, and show extended survival compared to historical controls. Toca 5 is a multicenter, randomized, open-label Phase 2/3 trial of Toca 511 and Toca FC versus standard of care administered to patients undergoing resection for first or second recurrence of GBM or AA. Phase 2 will enroll 170 patients. Primary endpoint is overall survival (OS). Key secondary endpoints are safety, objective response rate, clinical benefit rate, progression-free survival, and landmark OS. Key inclusion criteria are age 18-75 years, histologically proven GBM or AA, measurable disease preoperatively of less than 5cm, candidate for equal or greater 80% resection of enhancing tumor based on pre-operative evaluation, and KPS equal or greater to 70. Assays for immune monitoring will be performed and molecular profiling of resected tumor samples will be correlated efficacy." @default.
- W2539214151 created "2016-10-28" @default.
- W2539214151 creator A5005453167 @default.
- W2539214151 creator A5017814318 @default.
- W2539214151 creator A5026742889 @default.
- W2539214151 creator A5026869480 @default.
- W2539214151 creator A5028391222 @default.
- W2539214151 creator A5032439439 @default.
- W2539214151 creator A5039448543 @default.
- W2539214151 creator A5041536073 @default.
- W2539214151 creator A5047382443 @default.
- W2539214151 creator A5050381247 @default.
- W2539214151 creator A5052461495 @default.
- W2539214151 creator A5069589435 @default.
- W2539214151 creator A5070492766 @default.
- W2539214151 creator A5072518351 @default.
- W2539214151 creator A5072584423 @default.
- W2539214151 date "2016-10-01" @default.
- W2539214151 modified "2023-09-27" @default.
- W2539214151 title "PC3 - 151 Toca 5: A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined with Toca FC versus Standard of Care in Patients Undergoing Planned Resection for Recurrent Glioblastoma (GBM) or Anaplastic Astrocytoma (AA) (NCT02414165)" @default.
- W2539214151 doi "https://doi.org/10.1017/cjn.2016.379" @default.
- W2539214151 hasPublicationYear "2016" @default.
- W2539214151 type Work @default.
- W2539214151 sameAs 2539214151 @default.
- W2539214151 citedByCount "1" @default.
- W2539214151 countsByYear W25392141512023 @default.
- W2539214151 crossrefType "journal-article" @default.
- W2539214151 hasAuthorship W2539214151A5005453167 @default.
- W2539214151 hasAuthorship W2539214151A5017814318 @default.
- W2539214151 hasAuthorship W2539214151A5026742889 @default.
- W2539214151 hasAuthorship W2539214151A5026869480 @default.
- W2539214151 hasAuthorship W2539214151A5028391222 @default.
- W2539214151 hasAuthorship W2539214151A5032439439 @default.
- W2539214151 hasAuthorship W2539214151A5039448543 @default.
- W2539214151 hasAuthorship W2539214151A5041536073 @default.
- W2539214151 hasAuthorship W2539214151A5047382443 @default.
- W2539214151 hasAuthorship W2539214151A5050381247 @default.
- W2539214151 hasAuthorship W2539214151A5052461495 @default.
- W2539214151 hasAuthorship W2539214151A5069589435 @default.
- W2539214151 hasAuthorship W2539214151A5070492766 @default.
- W2539214151 hasAuthorship W2539214151A5072518351 @default.
- W2539214151 hasAuthorship W2539214151A5072584423 @default.
- W2539214151 hasBestOaLocation W25392141511 @default.
- W2539214151 hasConcept C126322002 @default.
- W2539214151 hasConcept C143998085 @default.
- W2539214151 hasConcept C203014093 @default.
- W2539214151 hasConcept C203092338 @default.
- W2539214151 hasConcept C31760486 @default.
- W2539214151 hasConcept C535046627 @default.
- W2539214151 hasConcept C71924100 @default.
- W2539214151 hasConcept C8891405 @default.
- W2539214151 hasConcept C90924648 @default.
- W2539214151 hasConceptScore W2539214151C126322002 @default.
- W2539214151 hasConceptScore W2539214151C143998085 @default.
- W2539214151 hasConceptScore W2539214151C203014093 @default.
- W2539214151 hasConceptScore W2539214151C203092338 @default.
- W2539214151 hasConceptScore W2539214151C31760486 @default.
- W2539214151 hasConceptScore W2539214151C535046627 @default.
- W2539214151 hasConceptScore W2539214151C71924100 @default.
- W2539214151 hasConceptScore W2539214151C8891405 @default.
- W2539214151 hasConceptScore W2539214151C90924648 @default.
- W2539214151 hasIssue "S4" @default.
- W2539214151 hasLocation W25392141511 @default.
- W2539214151 hasLocation W25392141512 @default.
- W2539214151 hasOpenAccess W2539214151 @default.
- W2539214151 hasPrimaryLocation W25392141511 @default.
- W2539214151 hasRelatedWork W1484790119 @default.
- W2539214151 hasRelatedWork W1608269846 @default.
- W2539214151 hasRelatedWork W2126237794 @default.
- W2539214151 hasRelatedWork W2133349049 @default.
- W2539214151 hasRelatedWork W2568506988 @default.
- W2539214151 hasRelatedWork W2789668336 @default.
- W2539214151 hasRelatedWork W2886193299 @default.
- W2539214151 hasRelatedWork W3089163820 @default.
- W2539214151 hasRelatedWork W4221026952 @default.
- W2539214151 hasRelatedWork W4282918911 @default.
- W2539214151 hasVolume "43" @default.
- W2539214151 isParatext "false" @default.
- W2539214151 isRetracted "false" @default.
- W2539214151 magId "2539214151" @default.
- W2539214151 workType "article" @default.